No Wall Street Crash for Biotech
When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday.
When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday. “It is the epicenter of Capitalization.” Buffet claims he feels exactly the same excitement today as he did then as a ten year old whenever he visits the Floor. He was in NYC to promote his son Peter’s book, “Life is What You Make It.”
This month, of course, marks the anniversary of The Wall Street Crash of 1929, the most devastating stock market crash in the history of the United States. The crash signaled the beginning of the 10-year Great Depression that affected all Western industrialized countries. We’re holding our breath, but so far it looks like clear sailing with no October surprises in store, especially for biotech.
As of yesterday, the 10 Best Biotech Stocks for 2013 were looking like this. (Source: TheStreet Ratings
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
